Vancouver, Canada – August 20, 2024 – Augurex Life Sciences Corp. today announced that it will be presenting a scientific poster at the upcoming Spondylo Congress, taking place in Ghent, Belgium, from September 5th to 7th, 2024.
Augurex’s poster, titled “Novel Diagnostic 14-3-3η Auto-Antibody Marker for Axial Spondyloarthritis: A Longitudinal Study,” highlights the company’s pioneering research and development activities in the diagnostic landscape of axial spondyloarthritis (AxSpA). The study will be presented by Dr. Anthony Marotta and aims to address the critical challenge of diagnosing AxSpA by validating the diagnostic utility of 14-3-3η auto-antibodies (AAb), and evaluating their modifiability over a one-year period.
The details of Augurex’s poster are as follows:
P 54. Novel Diagnostic 14-3-3η Auto-Antibody Marker for Axial Spondyloarthritis: A Longitudinal Study
Authors: A. Marotta, W.P. Maksymowych, S. Wichuk, N. Sidhu
Date & Time: Sep 6, 2024, 10:30 AM – 11:15 AM (attended)
Key Findings:
- The study involved 114 AxSpA patients and 86 presumed healthy individuals, with 14-3-3η AAb levels measured at baseline and year 1.
- Results indicated that median baseline levels of 14-3-3η AAb were significantly higher in AxSpA patients compared to healthy controls.
- The diagnostic performance of the 14-3-3η AAb, when analyzed alongside age, sex, and CRP levels, yielded an AUC of 0.82 and demonstrated a sensitivity of 76.2% and specificity of 74.1%.
- The study is the first to report on the modifiability of 14-3-3η AAb in AxSpA, showing potential for ongoing patient monitoring and management.
The full study will be presented during the congress, and Augurex is optimistic that these findings may pave the way for the integration of the 14-3-3η AAb marker into clinical practice, enhancing the diagnostic process and improving outcomes for patients with AxSpA. Mr. Neil Klompas, CEO of Augurex Life Sciences Corp., stated, “We are excited to share this innovative research at the Spondylo Congress, which we believe will significantly impact the diagnostic approach and treatment pathways for patients around the world with axial spondyloarthritis.”
About Augurex
Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test which detects the 14-3-3η protein, available as JOINTstat® in Canada, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte specific reagents to detect 14-3-3η are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. SPINEstat® expands Augurex’s biomarker-informed diagnostic autoimmune portfolio into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn and X.
Media Contact
Nima Mazinani
604-674-8231